This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vanhoutte, P. Articles by Hansson, L. Search for Related Content PubMed PubMed Citation Articles by Vanhoutte, P. Articles by Hansson, L.

Hypertension, Vol 11, 111-133, Copyright © 1988 by American Heart Association

ARTICLES

Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin

P Vanhoutte, A Amery, W Birkenhager, A Breckenridge, F Buhler, A Distler, J Dormandy, A Doyle, E Frohlich and L Hansson
Department of Physiology and Biophysics, Mayo Clinic, Rochester, MN 55905.

Aggregating platelets release serotonin, which induces contraction of most vascular smooth muscle by activation of S2-serotoninergic receptors. Serotonin released in the circulation may contribute to the increase in peripheral resistance of hypertension as the responsiveness of blood vessels from hypertensive animals and humans to the vasoconstrictor action of the monoamine is augmented. The data obtained with the new antihypertensive agent ketanserin may favor that interpretation. Ketanserin is a selective S2-serotoninergic antagonist with additional alpha 1-adrenergic blocking properties. In humans, it has a terminal half-life of 12 to 25 hours and is eliminated predominantly by the liver. The hemodynamic profile of ketanserin is that of a vasodilator drug with actions on both resistance and capacitance vessels. On short-term intravenous administration, it lowers blood pressure in hypertensive patients with minimal reflex changes in cardiovascular function. When given orally long term to hypertensive patients, ketanserin causes a sustained reduction in arterial blood pressure, comparable to that obtained with either beta- adrenergic blockers or diuretics. Several studies have shown a greater efficacy in older (greater than 60 years of age) than in younger patients independent of starting pressure. Side effects mainly consist of dizziness, somnolence, and dry mouth, but they are usually not severe. The mechanism underlying the antihypertensive effect of ketanserin is unclear. It cannot be attributed to either S2- serotoninergic or alpha 1-adrenergic blockade alone, but an interaction between the two effects appears to be required.

This article has been cited by other articles:

				S. W. Watts The love of a lifetime: 5-HT in the cardiovascular system Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R252 - R256. [Abstract] [Full Text] [PDF]

				S. W. Watts The beginning of a fantastic, unanswered question: is 5-HT involved in systemic hypertension? Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H915 - H916. [Abstract] [Full Text] [PDF]

				M. E. Chapman and R. F. Wideman Jr. Evaluation of the Serotonin Receptor Blocker Methiothepin in Broilers Injected Intravenously with Lipopolysaccharide and Microparticles Poult. Sci., December 1, 2006; 85(12): 2222 - 2230. [Abstract] [Full Text] [PDF]

				S. W. Watts Serotonin-Induced Contraction in Mesenteric Resistance Arteries: Signaling and Changes in Deoxycorticosterone Acetate-Salt Hypertension Hypertension, March 1, 2002; 39(3): 825 - 829. [Abstract] [Full Text] [PDF]

				S. W. Watts and G. D. Fink 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H944 - H952. [Abstract] [Full Text] [PDF]

				S. W. Watts, L. Gilbert, and R. C. Webb 5-Hydroxytryptamine2B Receptor Mediates Contraction in the Mesenteric Artery of Mineralocorticoid Hypertensive Rats Hypertension, December 1, 1995; 26(6): 1056 - 1059. [Abstract] [Full Text]